These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

951 related articles for article (PubMed ID: 33724461)

  • 21. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
    Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of newly diagnosed myeloma.
    Palumbo A; Rajkumar SV
    Leukemia; 2009 Mar; 23(3):449-56. PubMed ID: 19005483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP; Chen SL
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
    Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
    Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution.
    Jiménez-Segura R; Rosiñol L; Cibeira MT; Fernández de Larrea C; Tovar N; Rodríguez-Lobato LG; Bladé E; Moreno DF; Oliver-Caldés A; Bladé J
    Blood Cancer J; 2022 Sep; 12(9):135. PubMed ID: 36114167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Myeloma in the Time of COVID-19.
    Al Saleh AS; Sher T; Gertz MA
    Acta Haematol; 2020; 143(5):410-416. PubMed ID: 32305989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
    Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.
    Kitamura H; Kubota Y; Yamaguchi K; Kamachi K; Nishioka A; Yokoo M; Shindo T; Ando T; Kojima K; Kimura S
    Intern Med; 2018 Mar; 57(6):855-860. PubMed ID: 29151530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
    J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
    Ram R; Magen-Nativ H; Vidal L; Herscovici C; Peck A; Raanani P; Shpilberg O; Yeshurun M
    Clin Transplant; 2012; 26(5):E549-54. PubMed ID: 23061765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
    Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
    Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
    Vincent Rajkumar S
    Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Multiple myeloma with myelofibrosis at diagnosis and aggressive extramedullary relapse after autologous stem cell transplantation].
    Kodama Y; Saburi M; Kawano K; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
    Rinsho Ketsueki; 2024; 65(1):1-6. PubMed ID: 38311382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
    Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
    Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk adapted post-transplant maintenance in multiple myeloma.
    Vaxman I; Gertz M
    Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
    Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
    Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.